Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice
We hypothesized that by improving hand hygiene compliance in the operative environment, we would reduce horizontal transmission of pathogenic bacteria to surgical patients.
|Study Design:||Observational Model: Ecologic or Community
Time Perspective: Prospective
|Official Title:||Before and After Study Evaluating Deployment of the Sprixx GJ Personal Hand Hygiene Device in the Intra-Operative Environment|
- The presence of a positive culture on the previously sterile patient stopcock set, and the presence of multidrug resistant bacteria [ Time Frame: Beginning and end of surgical case ] [ Designated as safety issue: Yes ]
- Reduction of bacterial contamination on predetermined sites on the anesthesia machine [ Time Frame: Beginning and End of Surgical Case ] [ Designated as safety issue: Yes ]
- Decreased length of stay [ Time Frame: Postoperatively ] [ Designated as safety issue: Yes ]
- Nosocomial infection rates [ Time Frame: within 30 days postoperatively ] [ Designated as safety issue: Yes ]
- Mortality [ Time Frame: Within 30 days postoperatively ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples Without DNA
Environmental Bacterial Samples of Workspace
|Study Start Date:||July 2007|
|Study Completion Date:||October 2007|
|Primary Completion Date:||August 2007 (Final data collection date for primary outcome measure)|
Study group representative of standard practice
After treatment group with the personal hand hygiene device ie. Device Group.
We performed an observational study evaluating provider adherence to these techniques. We then sought to increase hand hygiene compliance through the use of a point of care alcohol based hand hygiene device. We hypothesized that increased hand hygiene compliance would reduce bacterial contamination of the anesthesia workspace and peripheral intravenous tubing, and ultimately reducing overall morbidity and mortality secondary to a reduction in nosocomial infection rates.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00617006
|United States, New Hampshire|
|Dartmouth-Hitchcock Medical Center|
|Lebanon, New Hampshire, United States, 03756|
|Principal Investigator:||Matthew D Koff, M.D. M.S.||Dartmouth-Hitchocck Medical Center|